Gold prices steady ahead of Fed decision, Trump’s tariff deadline
HAIFA, Israel - Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), a biotech company specializing in cell-based therapies with a current market capitalization of $27.94 million, has strengthened its intellectual property portfolio with new U.S. and Israeli patents for its immune cell expansion technologies. According to InvestingPro data, the company has demonstrated strong revenue growth of nearly 90% over the last twelve months, though it remains in development phase. These patents cover the company's advancements in the expansion of Mucosal-Associated Invariant T (MAIT) cells, which show promise in treating solid cancers.
The patented technology, titled "System and Methods For Immune Cells Expansion and Activation In Large Scale," focuses on methods for culturing immune cells using Pluri's proprietary 3D cell expansion bioreactors. While the company maintains a healthy liquidity position with a current ratio of 5.04, InvestingPro analysis indicates the company is currently burning through cash rapidly, typical for biotechnology companies in the development phase. This platform aims to provide a scalable solution for producing MAIT cells, which could serve as a first-in-class, ready-to-use, off-the-shelf therapy for cancer patients.
MAIT cells, derived from the human placenta, are known for their potential in targeting tumors through various mechanisms and for their ability to migrate directly to tumor sites. Pluri's technology is designed to mimic the natural lymph node environment, which is expected to maintain the integrity and functionality of expanded immune cells.
The announcement comes at a strategic time as the U.S. Food and Drug Administration recently approved therapies based on Tumor-infiltrating lymphocytes (TILs) and T Cell Receptor-engineered T cell (TCR-T) for solid cancers. Pluri's CEO, Yaky Yanay, expressed optimism about the company's position to potentially revolutionize solid tumor treatment and support other immunotherapy treatments.
The global immune cell engineering market is projected to reach approximately $11.7 billion by 2030, with the global cancer immunotherapy market estimated at $136 billion in 2025. With current revenues of $0.68 million in the last twelve months, Pluri shows significant growth potential in this expanding market. For deeper insights into Pluri's growth metrics and financial health indicators, InvestingPro subscribers have access to over 30 additional financial metrics and expert analysis. Pluri's growing patent estate, which includes over 250 patents pending, allowed, and granted, reflects its commitment to addressing the demand for advanced cell-based therapies.
Pluri's technology platform also supports the expansion of Tumor Infiltrating Lymphocytes (TILs), broadening the scope of potential immune cell therapies in cancer immunotherapy. This development has garnered attention in the TILs-focused research space.
The information in this article is based on a press release statement from Pluri Inc.
In other recent news, Pluri Inc. has announced its 2025 Annual Meeting of Shareholders, set for May 14, 2025, at its headquarters in Haifa, Israel. The announcement follows a recent SEC filing and highlights the company's adherence to corporate governance practices. In a significant development, Pluri Inc. has partnered with Ukrainian biobank Hemafund to advance its PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome in Ukraine. This collaboration, aimed at addressing regional radiation threats, is set for an initial three-year term and seeks to secure funding for a stockpile of 12,000 doses, potentially generating over $100 million for both parties.
Additionally, Pluri Inc. has been granted an extension by Nasdaq to meet the exchange's continued listing requirements. The company received a deficiency notice for failing to maintain the minimum required stockholders’ equity of $2.5 million but now has until May 24, 2025, to regain compliance. Pluri's management is committed to taking necessary measures to maintain its listing on the Nasdaq Capital Market. These recent developments underscore Pluri Inc.'s strategic initiatives and regulatory compliance efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.